Saturday 20 Apr, 2024 09:06 PM
Site map | Locate Us | Login
   HDFC Bank Q4 PAT climbs 37% YoY to Rs 16,512 cr    ABFRL board OKs to demerge Madurai Fashion & Lifestyle biz    Biocon gets nod from SAHPRA for Tacrolimus capsules    ICICI Bank board to mull fund raising proposal    Laurus Labs? Andhra Pradesh facility clears USFDA inspection    Landmark Cars inks LoI with M&M for opening showrooms, workshops in Hyderabad    Jio Financial posts PAT of Rs 311 crore for Q4 FY24    CRISIL upgrades rating of Tata Power's LT rating to 'AA+' with 'stable' outlook    IREDA Q4 PAT climbs 33% YoY to Rs 337 cr    HDFC AMC Q4 PAT climbs 44% YoY; recommends dividend of Rs 70/sh    Wipro Q4 PAT rises 5% QoQ to Rs 2,835 cr    Premier Explosives gains as board OKs 1:5 stock split    Hindustan Zinc slides after Q4 PAT decline 21% YoY    Axis Bank board to mull fund raising    Elecon Engg hits record high on strong Q4 outcome, board OKs 1:2 stock split 
Saravan Stocks
       
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
ITC, eClerx Services, Voltas, Subex in spotlight
03-Aug-22   08:27 Hrs IST

ITC: ITC said that following a strategic review of its business portfolio, the company has exited the Lifestyle Retailing Business.

eClerx Services: eClerx Services said that a meeting of board of directors of the company will be held on 9 August 2022 to consider the proposal for issuance of bonus equity shares of the company.

Voltas: Net profit for the quarter ended 30th June 2022 was at Rs. 110 crore as compared to Rs. 122 crore in the corresponding quarter last year. Consolidated total income was higher by 50% at Rs. 2795 crore in the quarter ended 30th June 2022 as compared to Rs. 1860 crore in the corresponding quarter last year.

Aurobindo Pharma: The United States Food and Drug Administration (US FDA) inspected the Company's Unit XI, an API non-antibiotic manufacturing facility situated at Pydibhimavaram, Srikakulam District, Andhra Pradesh, from July 25 to August 2, 2022. At the end of the inspection, the company was issued a 'Form 483' with 3 observations and none of these observations are related to data integrity.

Jubilant Pharmova: Jubilant Pharmova announced that the United States Food and Drug Administration (USFDA) has recently concluded audit of the Solid Dosage Formulations facility at Roorkee, India of Jubilant Generics, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited. The US FDA has issued six observations pursuant to the completion of the audit.

Subex: Subex and Jio Platforms (JPL) announced a partnership for its AI Orchestration Platform, HyperSense, which can enable telcos to deliver on the promise of AI across the data value chain. As per the collaboration, JPL will offer its Cloud Native 5G Core to telcos globally along with Subex's HyperSense for enabling closed loop network automation, product performance and customer experience analytics.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 32033346
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd